Clinical and immunologic evaluation of HIV-infected patients treated with dinitrochlorobenzene - 12/10/17

Doi : 10.1016/S0190-9622(94)70212-8

Raphael B. Stricker, MD ^⁎,^{^{1
From HemaCare Corporation; the Department of Medicine, California Pacific Medical Center; the Department of Dermatology, University of California School of Medicine; the DNCB Study Group, San Francisco; and Immunodiagnostic Laboratories, San Leandro.}}, Blaine F. Elswood, MA ^{^{1
From HemaCare Corporation; the Department of Medicine, California Pacific Medical Center; the Department of Dermatology, University of California School of Medicine; the DNCB Study Group, San Francisco; and Immunodiagnostic Laboratories, San Leandro.}}, Billi Goldberg ^{^{1
From HemaCare Corporation; the Department of Medicine, California Pacific Medical Center; the Department of Dermatology, University of California School of Medicine; the DNCB Study Group, San Francisco; and Immunodiagnostic Laboratories, San Leandro.}}, Cecilio Dumlao ^{^{1
From HemaCare Corporation; the Department of Medicine, California Pacific Medical Center; the Department of Dermatology, University of California School of Medicine; the DNCB Study Group, San Francisco; and Immunodiagnostic Laboratories, San Leandro.}}, Joanna Van Elk ^{^{1
From HemaCare Corporation; the Department of Medicine, California Pacific Medical Center; the Department of Dermatology, University of California School of Medicine; the DNCB Study Group, San Francisco; and Immunodiagnostic Laboratories, San Leandro.}}, Jim Henry ^{^{1
From HemaCare Corporation; the Department of Medicine, California Pacific Medical Center; the Department of Dermatology, University of California School of Medicine; the DNCB Study Group, San Francisco; and Immunodiagnostic Laboratories, San Leandro.}}, Edward E. Winger, MD ^{^{1
From HemaCare Corporation; the Department of Medicine, California Pacific Medical Center; the Department of Dermatology, University of California School of Medicine; the DNCB Study Group, San Francisco; and Immunodiagnostic Laboratories, San Leandro.}}, William L. Epstein, MD ^{^{1
From HemaCare Corporation; the Department of Medicine, California Pacific Medical Center; the Department of Dermatology, University of California School of Medicine; the DNCB Study Group, San Francisco; and Immunodiagnostic Laboratories, San Leandro.}}
^a San Francisco, California, USA
^b San Leandro, California, USA

^†Reprint requests: Raphael B. Strieker, MD, HemaCare Corporation, 450 Sutter St., Suite 1504, San Francisco, CA 94108.

Résumé

Background: Promotion of cell-mediated immunity appears to be an important goal in the control of HIV infection. Topical dinitrochlorobenzene (DNCB) stimulates systemic cell-mediated immunity via the induction of cutaneous delayed-type hypersensitivity.

Objective: Our goal was to evaluate the clinical and immunologic effects of chronic DNCB application in a group of 24 HIV-infected patients.

Methods: We observed the patients for a mean of 28 months (range, 14 to 44 months). Of the 24 patients, 13 continued weekly DNCB application throughout the study (the compliant group), and 11 discontinued DNCB use after a mean of 10.9 months (the noncompliant group).

Results: Two of the 13 compliant patients progressed to AIDS; none of these patients died. In contrast, AIDS developed in 5 of the 11 noncompliant patients and four of these patients died. Analysis of lymphocyte subsets revealed significant increases in natural killer cells and activated/cytotoxic CD8 T-cell subsets in the compliant group. In contrast, these cellular immune-related lymphocyte subsets decreased in the noncompliant subjects. Although CD4 T-cell levels decreased in both groups, there was a significantly greater drop in the noncompliant patients. CD8⁺CD38⁺ T cells increased significantly in both groups.

Conclusion: Chronic DNCB application appears to have a beneficial clinical and immunomodulatory effect in HIV-infected patients.

Le texte complet de cet article est disponible en PDF.

*	Supported in part by Research Grants 89.024C and 90.041C from California Pacific Medical Center and the Elizabeth Reed Taylor Foundation.

Export

Vol 31 - N° 3P1

P. 462-466 - septembre 1994 Retour au numéro

Article précédent

Prevention of recurrent aphthous stomatitis with colchicine: An open trial
Joseph Katz, Pnina Langevitz, Joshua Shemer, Shlomo Barak, Avi Livneh

| Article suivant

Atopic dermatitis: Triggering factors
Marie-Anne Morren, Bernhard Przybilla, Mia Bamelis, Bieke Heykants, Annelies Reynaers, Hugo Degreef

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Clinical and immunologic evaluation of HIV-infected patients treated with dinitrochlorobenzene - 12/10/17

Résumé

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL